RGBPP.US Regen BioPharma Inc

Healthcare Biotechnology USA Stocks
0.0008 USD
Close of Aug 22, 2026
0.0005 0.0675
Market cap
USD 123K
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.

Is RGBPP.US undervalued?

Graham number

The Graham number of Regen BioPharma Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Regen BioPharma Inc fundamental analysis

No fundamental analysis for Regen BioPharma Inc yet.

Regen BioPharma Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Regen BioPharma Inc

Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases. It also develops several products: HemaXellarate, a cellular therapeutic product derived from autologous stromal vascular fraction from adipose tissue; dCellVax, an autologous …

Full company profile